San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Precision IBD is raising $50,000,000.00 in a new round of investment. Sources indicate as part of senior management President and Chief Executive Officer, Scott Glenn played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Precision IBD

Owner and operator of a drug development precision medicine company intended to develop therapeutics for inflammatory bowel diseases. The company’s service focuses on developing proprietary screening panels and therapeutic compounds which have increased efficacy and safety for IBD and other inflammatory diseases with shared genetic susceptibility and biologic pathways, enabling medical researchers to develop drugs for treating inflammatory diseases like Ulcerative Colitis and Crohn’s disease.

To learn more about Precision IBD, visit http://www.precisionibd.com/

Contact:
Scott Glenn, President and Chief Executive Officer
619-987-7768

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved